Merck @Merck · 24 Jul 2026
Today we announced our initial post-approval access plans for our investigational HIV pre-exposure prophylaxis (PrEP). We are accelerating our access planning to help ensure that, if approved by the regulatory agency, this HIV prevention option can quickly reach those who need it https://t.co/fzJ7zIOKpf
14 533Views
28Likes
7Reposts
17Replies
4Quotes
1Bookmarks
Is that a lot?
32.0×vs this author's median454 views is typical
82Percentile for this authorof 11 recent posts
2.32×vs 100K–1M median6 271 views is typical
6.69%Reachviews ÷ followers
0.39%Engagement rateof viewers reacted